BSLN Basilea Pharmaceutica AG

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, March 14, 2025

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 2.5 million milestone payment.

David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer, resulting in this first sales milestone for the Asia Pacific and China region this year, which significantly surpasses previous sales milestones for the region. This underscores the continued progress in making Cresemba available to increasing numbers of patients suffering from life-threatening invasive mold infections in this region.”

The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region.

Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2023 and September 2024 amounted to USD 533 million, a 20 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1

About Cresemba® (isavuconazole)

Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and several additional countries including in the Asia Pacific region.5

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit .

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD



Head of Corporate Communications & Investor Relations

Basilea Pharmaceutica International Ltd, Allschwil

Hegenheimermattweg 167b

4123 Allschwil

Switzerland
Phone
E-mail

This press release can be downloaded from .

References

  1. IQVIA Analytics Link, September 2024. In-market sales reported as moving annual total (MAT) in US dollar.
  2. European Public Assessment Report (EPAR) Cresemba:  [Accessed: March 13, 2025]
  3. Summary of Product Characteristics (SmPC) Cresemba:  [Accessed: March 13, 2025]
  4. Full US prescribing information:  [Accessed: March 13, 2025]
  5. The registration status and approved indications may vary from country to country.

Attachment



EN
14/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Basilea Pharmaceutica AG

 PRESS RELEASE

Basilea gibt Verkaufsstart seines Antibiotikums Zevtera® (Ceftobiprol)...

Basilea gibt Verkaufsstart seines Antibiotikums Zevtera® (Ceftobiprol) in den USA bekannt Allschwil, 20. Mai 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute den Verkaufsstart seines Antibiotikums Zevtera® (Ceftobiprol-Medocaril zur Injektion) in den USA durch seinen Partner Innoviva Specialty Therapeutics Inc., einer vollständigen Tochtergesellschaft von Innoviva Inc. (NASDAQ: INVA), bekannt. Zevtera ...

 PRESS RELEASE

Basilea announces commercial availability of antibiotic Zevtera® (ceft...

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic Zevtera® (ceftobiprole medocaril for injection) is now commercially available in the United States through Basilea’s partner Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA). Zevtera is use...

Basilea Pharmaceutica AG: 1 director

A director at Basilea Pharmaceutica AG sold 400 shares at 44.000CHF and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

Starke Verkäufe von Cresemba® (Isavuconazol) in Japan lösen zweite Ums...

Starke Verkäufe von Cresemba® (Isavuconazol) in Japan lösen zweite Umsatzmeilensteinzahlung von Asahi Kasei Pharma an Basilea aus Allschwil, 24. April 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, berichtete heute, dass die Verkäufe des Antimykotikums Cresemba® (Isavuconazol) in Japan die Schwelle überschritten haben, durch welche eine Umsatzmeilensteinzahlung von seinem Partner Asahi Kasei Pharma (AKP) i...

 PRESS RELEASE

Strong sales for Cresemba® (isavuconazole) in Japan trigger second mil...

Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba® (isavuconazole) in Japan exceeded the threshold triggering a sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.7 million. This is the second mil...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch